--- title: "Johnson & Johnson | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 25.31 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/293660696.md" datetime: "2026-07-23T20:07:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293660696.md) - [en](https://longbridge.com/en/news/293660696.md) - [zh-HK](https://longbridge.com/zh-HK/news/293660696.md) --- # Johnson & Johnson | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 25.31 B Revenue: As of FY2026 Q2, the actual value is USD 25.31 B, beating the estimate of USD 25.06 B. EPS: As of FY2026 Q2, the actual value is USD 2.27, missing the estimate of USD 2.4267. EBIT: As of FY2026 Q2, the actual value is USD 6.809 B. #### Segment Revenue **Innovative Medicine Segment:**\- For the fiscal second quarter ended June 28, 2026, worldwide sales were $16,384 million, an increase of 7.8% compared to $15,202 million in the prior year’s second quarter, with U.S. sales at $9,979 million and international sales at $6,405 million.\- For the fiscal six months ended June 28, 2026, worldwide sales reached $31,810 million, an increase of 9.4% from $29,075 million in the prior year’s six-month period, consisting of $18,850 million in U.S. sales and $12,960 million in international sales. **MedTech Segment:**\- For the fiscal second quarter ended June 28, 2026, worldwide sales were $8,926 million, an increase of 4.5% from $8,541 million in the prior year’s second quarter, with U.S. sales at $4,554 million and international sales at $4,372 million.\- For the fiscal six months ended June 28, 2026, worldwide sales were $17,562 million, a worldwide increase of 6.0% from $16,561 million in the prior year’s six-month period, with U.S. sales at $9,013 million and international sales at $8,549 million. #### Operational Metrics **Fiscal Second Quarter Ended June 28, 2026 (compared to June 29, 2025):**\- Cost of products sold was $8,051 million (31.8% of sales), compared to $7,628 million (32.1% of sales).\- Gross profit was $17,259 million (68.2% of sales), up from $16,115 million (67.9% of sales).\- Selling, marketing and administrative expenses were $6,432 million (25.4% of sales), compared to $5,889 million (24.8% of sales).\- Research and development expense was $3,653 million (14.4% of sales), compared to $3,516 million (14.8% of sales).\- Interest income was - $219 million, compared to - $260 million.\- Interest expense, net was $281 million, compared to $308 million.\- Other (income) expense, net was $331 million, compared to $107 million.\- Restructuring charges were $34 million, down from $64 million.\- Earnings before provision for taxes on income were $6,747 million, compared to $6,491 million.\- Provision for taxes on income was $1,213 million, compared to $954 million.\- Net earnings were $5,534 million, compared to $5,537 million. **Fiscal Six Months Ended June 28, 2026 (compared to June 29, 2025):**\- Cost of products sold was $16,157 million (32.7% of sales), compared to $14,985 million (32.8% of sales).\- Gross profit was $33,215 million (67.3% of sales), up from $30,651 million (67.2% of sales).\- Selling, marketing and administrative expenses were $12,466 million (25.3% of sales), compared to $11,001 million (24.1% of sales).\- Research and development expense was $7,180 million (14.5% of sales), compared to $6,741 million (14.8% of sales).\- In-process research and development impairments were $36 million, compared to - $0 million.\- Interest income was - $448 million, compared to - $592 million.\- Interest expense, net was $553 million, compared to $512 million.\- Other (income) expense, net was $625 million, compared to - $7,214 million.\- Restructuring charges were $66 million, down from $81 million.\- Earnings before provision for taxes on income were $12,737 million, compared to $20,122 million.\- Provision for taxes on income was $1,968 million, compared to $3,586 million.\- Net earnings were $10,769 million, compared to $16,536 million. #### Cash Flow **Fiscal Six Months Ended June 28, 2026 (compared to June 29, 2025):**\- Net cash flows from operating activities were $11,130 million, up from $8,052 million.\- Net cash used for investing activities was - $2,150 million, significantly less than - $18,561 million in the prior period.\- Net cash used for financing activities was - $8,247 million, compared to net cash from financing activities of $4,757 million in the prior period. #### Unique Metrics **Intangible Assets and Goodwill (as of June 28, 2026):**\- Patents and trademarks, net: $24,815 million.\- Customer relationships and other intangibles, net: $5,949 million.\- Trademarks (indefinite lives): $1,744 million.\- Purchased in-process research and development: $15,721 million.\- Total intangible assets, net: $48,229 million.\- Goodwill was $48,479 million, with $14,755 million allocated to Innovative Medicine and $33,724 million to MedTech.\- The weighted average amortization period for patents and trademarks is approximately 12 years, and for customer relationships and other intangible assets, it is approximately 19 years.\- Estimated amortization expense for approved products for the next five years is approximately: $5,100 million in 2026, $4,400 million in 2027, $3,700 million in 2028, $3,600 million in 2029, and $3,500 million in 2030. **Equity Investments (as of June 28, 2026):**\- Equity investments with readily determinable value had a carrying value of $803 million.\- Equity investments without readily determinable value had a carrying value of $832 million. **Contingent Consideration (as of June 28, 2026):**\- The ending balance of contingent consideration liabilities was $823 million, an increase from $753 million at December 28, 2025. #### Future Outlook and Strategy Johnson & Johnson announced its intention in October 2025 to separate its Orthopaedics business. The company is exploring multiple paths to complete this planned separation, targeting completion within 18 to 24 months from the initial announcement. ### Related Stocks - [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md) ## Related News & Research - [EXPLAINER-Can J&J finally put the talc litigation behind it?](https://longbridge.com/en/news/294232224.md) - [BUZZ-Street View: J&J's strongest talc settlement push yet could clear legal cloud](https://longbridge.com/en/news/294044207.md) - [J&J Strikes $5.5B Talc Settlement after Years of Lawsuits; JNJ Stock Rises](https://longbridge.com/en/news/294022902.md) - [14:16 ETMilberg Helps Deliver Historic Uncapped Settlement for 70,000 Women in J&J Talcum Powder Litigation](https://longbridge.com/en/news/294100515.md) - [Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims](https://longbridge.com/en/news/294049280.md)